104 related articles for article (PubMed ID: 9933797)
21. IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells.
Inozume T; Hanada K; Wang QJ; Yang JC
J Immunother; 2009; 32(2):109-17. PubMed ID: 19238009
[TBL] [Abstract][Full Text] [Related]
22. Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor.
Singer K; Kastenberger M; Gottfried E; Hammerschmied CG; Büttner M; Aigner M; Seliger B; Walter B; Schlösser H; Hartmann A; Andreesen R; Mackensen A; Kreutz M
Int J Cancer; 2011 May; 128(9):2085-95. PubMed ID: 20607826
[TBL] [Abstract][Full Text] [Related]
23. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
24. Are renal cell carcinoma cells able to modulate the cytotoxic effect of tumor infiltrating lymphocytes by secretion of interleukin-6?
Steiner T; Junker U; Wunderlich H; Schubert J
Anticancer Res; 1999; 19(2C):1533-6. PubMed ID: 10365139
[TBL] [Abstract][Full Text] [Related]
25. Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases.
Perut F; Cenni E; Unger RE; Kirkpatrick CJ; Giunti A; Baldini N
Int J Oncol; 2009 May; 34(5):1387-93. PubMed ID: 19360351
[TBL] [Abstract][Full Text] [Related]
26. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Frankenberger B; Pohla H; Noessner E; Willimsky G; Papier B; Pezzutto A; Kopp J; Oberneder R; Blankenstein T; Schendel DJ
Clin Cancer Res; 2005 Mar; 11(5):1733-42. PubMed ID: 15755994
[TBL] [Abstract][Full Text] [Related]
27. Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells.
Smyth GP; Stapleton PP; Barden CB; Mestre JR; Freeman TA; Duff MD; Maddali S; Yan Z; Daly JM
Ann Surg Oncol; 2003 May; 10(4):455-62. PubMed ID: 12734096
[TBL] [Abstract][Full Text] [Related]
28. Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma.
Ning H; Shao QQ; Ding KJ; Gao DX; Lu QL; Cao QW; Niu ZH; Fu Q; Zhang CH; Qu X; Lü JJ
Chin Med J (Engl); 2012 Jun; 125(12):2120-5. PubMed ID: 22884140
[TBL] [Abstract][Full Text] [Related]
29. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type.
Ramp U; Jaquet K; Reinecke P; Schardt C; Friebe U; Nitsch T; Marx N; Gabbert HE; Gerharz CD
J Urol; 1997 Jun; 157(6):2345-50. PubMed ID: 9146668
[TBL] [Abstract][Full Text] [Related]
30. TNF-alpha induction of GM2 expression on renal cell carcinomas promotes T cell dysfunction.
Raval G; Biswas S; Rayman P; Biswas K; Sa G; Ghosh S; Thornton M; Hilston C; Das T; Bukowski R; Finke J; Tannenbaum CS
J Immunol; 2007 May; 178(10):6642-52. PubMed ID: 17475896
[TBL] [Abstract][Full Text] [Related]
31. Characterization of interleukin-4 receptors expressed on human renal cell carcinoma cells.
Obiri NI; Puri RK
Oncol Res; 1994; 6(9):419-27. PubMed ID: 7703528
[TBL] [Abstract][Full Text] [Related]
32. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the response of dendritic cells and regulatory T cells to tumor antigens in patients with renal cell carcinoma.
Hou MM; Chang JW; Pang ST; Chiang YJ; Shen YC; Liao SK; Hsieh JJ; Yeh KY; Chang NJ; Chuang CK
Chang Gung Med J; 2010; 33(1):25-35. PubMed ID: 20184792
[TBL] [Abstract][Full Text] [Related]
34. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
[TBL] [Abstract][Full Text] [Related]
35. JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients.
Cavalcanti E; Gigante M; Mancini V; Battaglia M; Ditonno P; Capobianco C; Cincione RI; Selvaggi FP; Herr W; Storkus WJ; Gesualdo L; Ranieri E
J Biomed Biotechnol; 2010; 2010():935764. PubMed ID: 20339477
[TBL] [Abstract][Full Text] [Related]
36. Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation.
Müller CA; Markovic-Lipkovski J; Klatt T; Gamper J; Schwarz G; Beck H; Deeg M; Kalbacher H; Widmann S; Wessels JT; Becker V; Müller GA; Flad T
Am J Pathol; 2002 Apr; 160(4):1311-24. PubMed ID: 11943716
[TBL] [Abstract][Full Text] [Related]
37. Transforming growth factor-beta1 and renal cell cancer: cell growth, mRNA expression and protein production of cytokines.
Shimabukuro T; Ohmoto Y; Naito K
J Urol; 2003 May; 169(5):1865-9. PubMed ID: 12686863
[TBL] [Abstract][Full Text] [Related]
38. Differential expression of cytokines and cytokine receptors in renal cell carcinoma.
Steiner T; Junker U; Salamon A; Nuske K; Schubert J
Urol Int; 2001; 66(3):140-4. PubMed ID: 11316975
[TBL] [Abstract][Full Text] [Related]
39. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
[TBL] [Abstract][Full Text] [Related]
40. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
